Background: Corticosteroid (CS) treatment has been established as the first anti-inflammatory treatment for adults and children with asthma. However, a subset of patients fails to respond to combined systemic and inhaled CS treatment. Objective: This study was aimed at further understanding CS resistance among children with severe asthma. Methods: High-resolution metabolomics was performed on urine samples from CS-respondent (n 5 15) and CSnonrespondent (n 5 15) children to determine possible urine biomarkers related to CS resistance. The metabolic phenotypes of CS responders and CS nonresponders were analyzed using bioinformatics including Manhattan plot with false-discovery rate, hierarchical cluster analysis, Kyoto Encyclopedia Genes and Genomes, and Mummichog pathway analysis. 1 ). Tyrosine metabolism, degradation of aromatic compounds, and glutathione metabolism are suggested to be significant pathways relating to CS resistance. Conclusions: High-resolution metabolomics is a promising approach in asthma research. Five candidate markers were identified to be related to CS-resistant children with severe asthma. These compounds, upon validation, may contribute further in the understanding of CS resistance among children with severe asthma through the use of urine. (J Allergy Clin Immunol 2017;139:1518-24.) 
Asthma is the most common chronic airway disorder in children and is characterized by inflammation and hypersensitivity of the airways. Although asthma treatment currently involves a ''one-size fits-all'' approach with graded steps of bronchodilators and anti-inflammatory agents that balance effective therapy with minimal adverse side effects, [1] [2] [3] asthma is considered a multifactorial disease, 4, 5 with diverse overlapping pathologies and phenotypes. [6] [7] [8] This contributes to significant heterogeneity in the clinical manifestations and treatment responses associated with the disorder.
Corticosteroids (CSs) are the cornerstone of asthma treatment. [9] [10] [11] Inhaled CSs are the first-line therapy for asthma, whereas systemic CSs are used for immediate treatment due to their rapid onset of effect and relatively easy administration. Despite their efficacy, CS-associated side effects are common. Moreover, a subset of children with severe asthma fails to respond to combined systemic and inhaled CS treatment despite very high doses and prolonged treatment. 12, 13 Although the prevalence of CS resistance among children is very low, these children account for a disproportionate health care spending. 14 There are a growing number of studies focused on molecular mechanisms of CS resistance in asthma. [15] [16] [17] [18] Because the long-term prognosis for children with severe asthma may be directly related to CS responsiveness, early and reliable identification of CS responsiveness is important. 13 Therefore, there is a need to further understand the molecular features of CS resistance among these children. A number of clinical tools, including the measurement of exhaled gases such as nitric oxide, 19, 20 as well as inflammatory markers, have been used to characterize airway inflammation, but the clinical utility of these techniques remains unproven. 21, 22 In addition, bronchoscopy is invasive and often impractical in very young children. 23 Therefore, more sensitive and practical diagnostic methods are needed. The identification of noninvasive biomarkers in the urine of patients with asthma would be extremely beneficial not only for early identification of CS resistance but also for future development of novel treatments. High-resolution metabolomics (HRM) offers an important advantage in analyzing highly complex metabolite mixtures such as biological extracts because the detection of mass-tocharge ratios (m/z) with 5 ppm or better mass resolution and mass accuracy substantially decreases the demand for physical separation before detection. 24, 25 Minimal extraction avoids the perturbation of the relative abundance of the metabolites in the sample. HRM is often used on urine samples because of the high sensitivity and selectivity of mass spectrometry techniques; these techniques have become the methods of choice in characterizing the human metabolome. 26, 27 This study aimed to use HRM to describe metabolomics patterns exhibited by CS resistance among children with severe asthma. The study examined differences in metabolic profiles of urine and identified biomarkers that differed between CS-resistant and CS-responsive children with severe asthma through the use of high-throughput mass spectrometry.
METHODS Chemicals
LC-MS-grade water (Tedia, Fairfield, Ohio), acetonitrile (Burdick & Jackson, Muskegon, Mich), and formic acid (Fluka, St Louis, Mo) were used for the mobile phase in this study.
Characteristics of the study population
The study was approved by the Emory University Institutional Review Board. Informed consent was obtained from all participating children and their legal guardians. Children aged 6 to 17 years with physician-diagnosed asthma treated with high-dose inhaled CS and a second controller medication were recruited from an outpatient severe asthma clinic in Atlanta, Georgia. All children met published criteria for severe asthma including adherence to inhaled CS evidenced by 10 or more monthly electronic prescription refills over the previous 12 months. 28 Each participant had a history of either 12% or more reversibility in the FEV 1 after bronchodilator administration or airway hyperresponsiveness to methacholine, evidenced by a provocative concentration of methacholine of 16 mg/mL or less. Exclusion criteria included premature birth before 35 weeks' gestation, aspiration disorders, vocal cord dysfunction, avascular necrosis, diabetes mellitus, historical or current bronchopulmonary aspergillosis, treatment with nonsteroidal anti-inflammatory drugs or omalizumab, chronic bone disorders, or bone fractures within the previous 6 months. All participants were stable at the time of baseline characterization with no signs of acute respiratory illnesses. If a recent exacerbation was reported, the first visit was conducted 4 weeks after completion of an oral or injectable systemic corticosteroid burst. Permission to proceed with this study was granted by the Emory University Institutional Review Board. Informed written consent was obtained from the legally authorized representatives of eligible children and assent was also obtained from participants 6 years of age and older. After consent was obtained, participants completed 2 research characterization visits separated by 14 days. Intramuscular triamcinolone (1 mg/kg, 60 mg maximum dose) was administered in the gluteal muscle at the completion of the first visit to all participating children. Spirometry (KoKo PDS, Ferraris, Louisville, Colo) was performed at baseline and the best of 3 vital capacity maneuvers was interpreted. Participants were asked to withhold bronchodilator medication before the study visits (ie, > _4 hours for short-acting beta agonists and > _12 hours for long-acting beta agonists).
Urine samples were collected from children with asthma (n 5 30) enrolled in a previous study focused on the metabolic phenotypes accompanying severe asthma. 29 Children with severe asthma (n 5 30), by definition, were treated with higher doses of inhaled CSs (median, 1000 vs 250 mg fluticasone equivalent/d, P <.001), yet they required greater health care utilization for asthma as well as having increased airflow limitation, more impaired asthma control, and a compromised quality of life. In addition, no child with severe asthma displayed complete corticosteroid responsiveness per our composite definition (Table I) . Corticosteroid resistance was defined by persistently poor asthma control with symptoms greater than twice weekly, in addition to less than 15% improvement in the FEV 1 , 2 weeks after systemic triamcinolone administration.
In this regard, 15 children had only partial responsiveness while 15 children had improved clinical responses to systemic triamcinolone administration (Fig 1) .
Liquid chromatography coupled with Fouriertransform mass spectrometry
All the samples were run in triplicate. Aliquots (100 mL) of supernatant samples were treated with acetonitrile (2:1, v/v), spiked with a 2.5 mL internal standard mix, and centrifuged at 14,000g for 5 minutes at 48C to remove protein, as described previously. 30 Analyses were done using MS-mode scanning from an m/z range of 85 to 850 in the FT detector at a resolution of 50,000 with the wide range scan mode and 3 million ions per scan using a Thermo LTQ-FT mass spectrometer (Thermo Fisher Scientific, San Jose, Calif). HRM was suitable for this purpose and detected 8570 total metabolites in urine. The triplicated runs were averaged, log 2 transformed, and quantile normalized for the subsequent multivariate analysis. 
Data collection, processing, and analysis
Data were preprocessed using the R package apLCMS, from which the total features of the samples were determined. 31 HRM was suitable for this purpose and detected 8570 total metabolites in urine. The triplicated runs were averaged, log 2 transformed, and quantile normalized for the subsequent multivariate analysis. Baseline differences between CS-responder (CS-R) children and CS-nonresponder (CS-NR) children in urine samples were assessed at visit 2 and were evaluated using the false-discovery rate (FDR). Furthermore, the metabolic profiles were discriminated using Limma-hierarchical cluster analysis to separate 2 groups in association with metabolites. Limma is originally a package of linear models for microarray to analyze the gene expression data arising from microarray or RNA-Seq technologies from Bioconductor. 32 Pathway analysis for the m/z of metabolites used the Kyoto Encyclopedia of Genes and Genomes (KEGG) and Mummichog, [33] [34] [35] which showed that less than 10% of metabolites were redundant with others in terms of elemental composition. In addition, identified metabolites were annotated using the METLIN Mass Spectrometry Database. 36 For such metabolites, quantification relative to stable isotope internal standards had coefficients of variation (5%-10%) and sensitivity similar to that of other methods, thus being sufficient to allow for targeted analyses of selected chemicals within the context of an information-rich nontargeted profiling of all m/z detected within biological samples.
RESULTS

Manhattan plot with FDR
A Manhattan plot (Fig 2, A) combines multiple testing correction, which enables visual identification of statistically significant data points (metabolites) that display largemagnitude changes. Multiple testing corrections such as FDR adjust P values (q values) derived from multiple statistical tests to correct for the occurrence of false positives. The Y axis represents the 2log10-adjusted value of the raw P value between CS-R and CS-NR children. The X axis indicates m/z ranging from 85 to 850 m/z. The dotted line shown is the FDR significant level; therefore, any m/z above this line were significantly different between the 2 groups at FDR q 5 0.05. The total number of significant features was 30 out of the 8570 detected. The FDR q 5 0.05, 1.7 [-log (FDR q 5 0.05)] appears as a green dotted line (Fig 2, A) .
Two-way hierarchical cluster analysis on 30 significant features
A 2-way hierarchical cluster analysis (HCA) was performed: the top panel displayed sample classification, and the left panel visualized metabolites clustering to identify which metabolites are the most important for sample grouping. In this study, HCA was performed using 30 significant metabolites at FDR q 5 0.05, which were the key components to separate 2 groups (Fig 2, A) . HCA resulted in good separation between CS-R (red bar) and CS-NR (green bar) children except for 2 CS-R children who were grouped with CS-NR.
Annotation with METLIN database and KEGG pathway analysis using 30 significant metabolites Significantly altered m/z features between CS-R and CS-NR were annotated using the METLIN database and mapped the features distribution on the KEGG human metabolic pathways. The mapped significant features between CS-R and CS-NR children are shown as black dots on the pathway map in Fig 3. The important pathways influenced by significantly altered m/z are listed as tyrosine metabolism, degradation of aromatic compounds, and glutathione metabolism in Table II .
The relative concentrations of urine features altered significantly 
Mummichog pathway analysis
Mummichog analysis identified that tyrosine and xenobiotics metabolism was affected at a P value of .01 and .03, respectively, by CS resistance. The important module (P 5 .0002) that appeared in tyrosine metabolism is shown in Fig 6. The concentration of 3,4-dihydroxy-L-phenylalanine and 3-methoxy-4-hydroxyphenyl(ethylene)glycol increased significantly (FDR q 5 0.05) in CS-NR children compared with CS-R children. However, S-methyl homocysteine and S-methyl methionine decreased in CS-NR children, but not to a statistically significant level.
An analysis between children with mild-to-moderate and children with severe asthma was also conducted to see the specificity of the selected biomarkers (see Figs E1-E4 in this article's Online Repository at www.jacionline.org). The findings showed that although there was a high separation between the mild and severe cases, the 5 selected compounds were not found significant. This shows the specificity of the selected compounds toward CS resistance among those with severe asthma.
DISCUSSION
The identification of predictive biomarkers in urine as a surrogate tissue for monitoring changes in metabolic profile occurring in lung airway tissue requires highly sensitive instruments to ensure measurement of the fmol-pmol quantities of metabolites in blood. This surrogate urine sample is expected to contain a much lower concentration of metabolites compared with the local tissue in those with asthma. Thus, HRM with mass Metabolic pathways 21 Tyrosine metabolism 3 Diiodo-L-tyrosine Dihydroxy-L-phenylalanine 3-Methoxy-4-hydroxyphenylethyleneglycol Degradation of aromatic compounds 2 Dihydronaphthalene-1,2-diol 2-Hydroxy-6-oxo-6-(2-hydroxyphenyl)-hexa-2,4-dienoate Glutathione metabolism 2 Cys-Gly gamma-Glutamylcystine spectrometry proves to be the best method for metabolic profiling in this study because HRM's high sensitivity and selectivity enables it to identify putative biomarkers in urine.
In this study, HRM selected 30 significant features between CS-R and CS-NR children in severe asthma sufferers. Among these, the 2 metabolites from glutathione (GSH) metabolism, g-glutamylcysteine and cysteine-glycine, were changed significantly between 2 groups. Fig 4 describes g-glutamylcysteine as low in CS-NR children, suggesting a decrease in GSH synthesis. Furthermore, cysteine-glycine increased in CS-NR children, meaning a higher degradation in CS-NR children. 37 GSH is one of the most important antioxidants for preventing oxidative stress. [38] [39] [40] This result demonstrated that the GSH pathway would be the target for CS resistance. Interestingly, dihydronicotinic acid was higher in CS-NR children compared with CS-R children, which led to smoking as an important factor for CS resistance. Other evidence linked to smoking was that the level of 1,2-dihydronaphthalene-1,2-diol increased in CS-NR children compared with CS-R children. This aromatic chemical might suggest an association with smoking because naphthalene is present in cigarette smoke. 41 Tyrosine metabolism may be affected by CS resistance because 3,4-dihydro-L-phenylalanine increased in CS-NR children (Fig 6) . This chemical is involved in catecholamine biosynthesis such as noradrenaline and adrenaline, causing bronchoconstriction. The 5 detected putative biomarkers provide solid evidence of the association with CS resistance.
The need for personalized medicine has been addressed in many areas such as airway inflammation, cancer, diabetes, and heart disease. The development and refinement of personalized approaches for asthma are particularly relevant because of multiple phenotypes. Identification and treatment of children with severe asthma in the clinical setting remains difficult, and the results from this study will be important given the significant cost and morbidity associated with the disorder and may aid in the development of personalized treatment regimes in the future. However, replication of the results in other populations is ultimately needed. 
